CD47 and breast cancer: Also, in several preclinical studies, researchers have investigated potential therapeutic approaches combining anti-CD47 strategies with anti-CD20 strategies for lymphoma, anti-HER2 strategies for breast cancer, and anti-EGFR strategies for colorectal cancer.